BRAF and colorectal carcinoma: Two major clinical trials conducted in Europe and the United States reported consistent results: the retrospective study of the PETACC-3, EORTC 40993, SAKK 60-00 trials showed on one hand an independent negative prognostic value of the BRAF mutation in Stage II/III CRC (HR 1.78, 95% CI 1.15–2.76) [40].